The Lupus Foundation of America said Tuesday that a discussion of the positive results of a recent Phase II clinical study of Anifrolumab, a potential treatment for systemic lupus, is available on its website.
Anifrolumab is an antibody that fights against the Type I interferon (IFN) receptor that inhibits the activity of all Type I IFNs, from which lupus often originates.
In the study, Anifrolumab
produced positive results in 34.4 percent of the patients who were administered 300-milligram doses and in 28.8 percent of the patients who received 1,000-milligram doses.
Dr. Richard Alan Furie, chief of the Division of Rheumatology at North Shore-LIJ Health System, discusses the results in the podcast.
Data gleaned from the study was presented Monday during the American College of Rheumatology's annual scientific meeting in San Francisco.
Phase II clinical study of Anifrolumab shows positive lupus treatment results
Organizations in this Story
Want to get notified whenever we write about LUPUS Foundation of America ?
Next time we write about LUPUS Foundation of America, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.Sign-up for Alerts